Some economics on personalized and predictive medicine on personalized and predictive medicine

Autor: Rodríguez Ibeas, RobertoAntoñanzas Villar, Fernando JesúsJuárez Castelló, Carmelo Arturo

Tipo de documento: Artículo de revista

Revista: European Journal of Health Economics. ISSN: 1618-7598. Año: 2015. Número: 9. Volumen: 16. Páginas: 985-994.

JCR (datos correspondientes al año 2014):
Social Sciences  Área: ECONOMICS  Quartil: Q1  Lugar área: 53/333  F. impacto: 1,774 
Social Sciences  Área: HEALTH POLICY & SERVICES  Quartil: Q2  Lugar área: 29/71  F. impacto: 1,774 

SCIMAGO (datos correspondientes al año 2014):
,768  SNIP: 1,05 




  • Gibson, W.M., Can personalized medicine survive? (1971) Can Fam Physician, 17 (8), pp. 29-88. , COI: 1:STN:280:DC%2BC3cngt1Skuw%3D%3D, PID: 20468669
  • Antoñanzas, F., Rodríguez-Ibeas, R., Hutter, M.F., Lorente, R., Juárez, C., Pinillos, M., Genetic testing in the European Union: does economic evaluation matter? (2012) Eur J Health Econ, 12 (5), pp. 651-662
  • Payne, K.A., Frueh, F.W., Sohal, J., Enhancing the health economic value of retrospective and prospective real-world studies with pharmacogenomic testing: opportunities and challenges associated with an integrated personalized medicine approach (2012) Value Health, 15 (4), pp. 159-160
  • Lester, D.S., Will personalized medicine help in ‘transforming’ the business of healthcare? (2009) Pers Med, 6 (5), pp. 555-565
  • Lewis, J.R.R., Lipworth, W.L., Kerridge, I.H., Day, R.O., The economic evaluation of personalised oncology medicines: ethical challenges (2013) Med J Aust, 199 (7), pp. 471-473. , PID: 24099207
  • Schildmann, J., Marckmann, G., Vollmann, J., Personalized medicine. medical, ethical, legal, and economic analysis (2013) Ethik in Der Med, 25 (3), pp. 169-172
  • Redekop, W.K., Mladsi, D., The faces of personalized medicine: a framework for understanding its meaning and scope (2013) Value Health, 16, pp. 54-59
  • Trusheim, M.R., Berndt, E.R., Douglas, F.L., Stratified medicine: strategic and economic implications of combining drugs and clinical biomarkers (2007) Nat Rev Drug Discov, 6 (4), pp. 287-293. , COI: 1:CAS:528:DC%2BD2sXjs1SisLw%3D, PID: 17380152
  • Kalia, M., Personalized oncology: recent advances and future challenges (2013) Metabolism, 62 (1), pp. 11-14. , COI: 1:CAS:528:DC%2BC38XhtlOnsLzI, PID: 22999010
  • Meckley, L.M., Neumann, P.J., Personalized medicine: factors influencing reimbursement (2010) Health Policy, 94 (2), pp. 91-100. , PID: 19815307
  • Greeley, S.A.W., John, P.M., Winn, A.N., Ornelas, J., Lipton, R.B., Philpson, L.H., The cost-effectiveness of personalized genetic medicine the case of genetic testing in neonatal diabetes (2011) Diabetes Care, 34 (3), pp. 622-627. , PID: 21273495
  • Postma, M.J., Boersma, C., Vandijck, D., Vegter, S., Le, H.H., Annemans, L., Health technology assessments in personalized medicine: illustrations for cost-effectiveness analysis (2011) Expert Rev Pharmacoecon Outcomes Res, 11 (4), pp. 367-369. , PID: 21831013
  • Annemans, L., Redekop, K., Payne, K., Current methodological issues in the economic assessment of personalized medicine (2013) Value Health, 16 (6), pp. 20-26. , PID: 24034308
  • Sahlin, N., Hermeren, G., Personalised, predictive and preventive medicine: a decision-theoretic perspective (2012) J Risk Res, 15 (5), pp. 453-457
  • Chiappori, P.A., (2006) The Welfare of Predictive Medicine, in Competitive Failures in Insurances Markets: Theory and Policy Implications, pp. 55-78. , MIT Press, Cambridge
  • Ferlay, J., Soerjomataram, I., Ervik, M., Dikshit, R., Eser, S., Mathers, C., Rebelo, M., Bray, F., GLOBOCAN 2012 v1.0 (2013) Cancer incidence and mortality worldwide: IARC cancerbase, 11. ,, Lyon, France: International Agency for Research on Cancer
  •, National Institute for Health and Care Excellence (NICE): KRAS Mutation testing of tumours in adults with metastatic colorectal cancer: diagnostic assessment report. (2013). Accessed 05 July 2014Behl, A.S., Cost-effectiveness analysis of screening for KRAS and BRAF mutations in metastatic colorectal cancer (2012) J Natl Cancer Inst, 104 (23), pp. 1785-1795. , PID: 23197490
  • Thierry, A.R., Clinical validation of the detection of KRAS and BRAF mutations from circulating tumor DNA (2014) Nat Med, 20, pp. 430-435. , COI: 1:CAS:528:DC%2BC2cXks12rsrw%3D, PID: 24658074
  •, Prostate Cancer Research Institute: PCA3: A genetic marker of prostate cancer. Accessed 02 June 2014Barbera, M., Pepe, P., Paola, Q., Aragona, F., PCA3 score accuracy in diagnosing prostate cancer at repeat biopsy: our experience in 177 patients (2012) Arch Ital Urol Androl, 84 (4), pp. 227-229. , PID: 23427750
  • Bradley, L.A., Palomaki, G.E., Gutman, S., Samson, D., Aronson, N., Comparative effectiveness review: prostate cancer antigen 3 testing for the diagnosis and management of prostate cancer (2013) J Urol, 190 (2), pp. 389-398. , COI: 1:CAS:528:DC%2BC3sXpslGiurc%3D, PID: 23545099
  •, Federación Española del Síndrome X Frágil:  ¿Qué es el Sindrome X-frágil?. Accessed 06 Feb 2014Weck, K.E., Zehnbauer, B., Datto, M., Schrijver, I., Molecular genetic testing for fragile X syndrome: laboratory performance on the College of American Pathologists proficiency surveys (2001–2009) (2012) Genet Med, 14 (3), pp. 306-312. , COI: 1:CAS:528:DC%2BC38Xjs1SrtbY%3D, PID: 22241100
  • Towse, A., Garrison, L.P., Economic incentives for evidence generation: promoting an efficient path to personalized medicine (2013) Value Health, 16 (6), pp. 39-43. , PID: 24034311
  • O’Donnell, J.C., Personalized medicine and the role of health economics and outcomes research: issues, applications, emerging trends, and future research (2013) Value Health, 16 (6), pp. 1-3. , PID: 24034305
  • Rogowski, W., Payne, K., Schnell-Inderst, P., Manca, A., Rochau, U., Jahn, B., Concepts of "
  • Personalization"
  • in personalized medicine: implications for economic evaluation (2014) PharmacoEconomics